Q: Pharma supply chains have faced unprecedented challenges in recent years. Where do you see AI making the biggest impact?

"The pharmaceutical industry operates in one of the most complex and highly regulated supply chain environments. Any delay, disruption, or lack of visibility can have serious consequences - not just financially, but for patient health.

The recent LogiPharma survey confirms two insights. First, pharma companies have already seen the benefits of AI in inventory, customer service, and quality, with 40% of executives reporting gains in the past year. Second, supply chain visibility and risk management are top priorities for future AI improvements, with 24% of executives citing them as the biggest opportunities."

Q: Many companies are investing in AI, but when do they expect to see returns?

"They don’t expect immediate results - 65% of pharma executives expect ROI from AI investments within 2-3 years, while another 32% anticipate returns in 3-5 years. This tells us that companies aren’t just looking for quick wins; they see AI as a long-term, strategic investment.

Pharma supply chains are using AI for risk mitigation, compliance, and efficiency - driving the biggest gains in disruption prevention, manufacturing planning, and faster logistics decisions.

Take AI-powered exception management, for example, solutions like Movement AI enables companies to detect potential delays, assess the impact in real time, and recommend proactive solutions. Supply chain teams can resolve problems 20% faster and reduce time spent on manual data quality tasks by 75%."

Q: Despite AI’s potential, the survey shows that most pharma supply chains are still at a mid-level of AI maturity. What do you make of that?

"That’s right—most respondents rated their AI maturity at level 3 out of 5, meaning they’ve started using AI but haven’t fully scaled it across their supply chain operations. AI is transforming supply chains in phases: first, by improving inventory, customer service, and quality assurance; second, as over half of pharma executives now use it to strengthen supplier relationships; and third, by influencing broader business decisions, from risk management to manufacturing planning."

Q: What is holding pharma supply chain leaders back from better AI maturity?

"Very few pharma executives rated their company’s level of maturity lower than a 3, so the biggest challenge isn’t lack of interest - it’s data quality, integration, and trust in AI-driven decisions.

Pharma supply chains generate massive data volumes, but fragmented data limits AI’s value. AI-powered data correction automatically fills gaps, fixes errors, and delivers real-time visibility without human intervention.

Another challenge is ease of use. Many supply chain teams aren’t data scientists - they need AI that works intuitively and provides instant answers. That’s why conversational AI, like MO, our AI-powered supply chain assistant, is gaining traction. You can simply type a question - “Which shipments are at risk due to global disruptions?” - and get a real-time, actionable response."